Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.

Current medicinal chemistry - 1 Jan 2014

Takeuchi Toshihide, Popiel H Akiko, Futaki Shiroh, Wada Keiji, Nagai Yoshitaka

Abstract excerpt

The polyglutamine (polyQ) diseases including Huntington's disease and spinocerebellar ataxias are a group of inherited neurodegenerative diseases that are caused by an abnormal expansion of the polyQ stretch in disease-causative proteins. The expanded polyQ stretches are intrinsically unstable and are prone to form insoluble aggregates and inclusion bodies. Recent studies have revealed that the expanded polyQ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurodegenerative Diseases
Share to Peptides
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Aggregation, Pathological

Source

Identifiers

PMID: 24533807
DOI: 10.2174/0929867321666140217124038

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.PMID 24533807Read ↗

Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine DiseasesSemantic proximity Read ↗

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.Semantic proximity Read ↗

Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine DiseasesSemantic proximity Read ↗

Polyglutamine (PolyQ) Diseases: Genetics to TreatmentsSemantic proximity Read ↗

Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disordersSemantic proximity Read ↗

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense TherapiesSemantic proximity Read ↗

Polyglutamine Diseases and Transport ProblemsSemantic proximity Read ↗

Neurotoxic protein oligomerisation associated with polyglutamine diseases.Semantic proximity Read ↗

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of NeurodegenerationSemantic proximity Read ↗

Polyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?Semantic proximity Read ↗

Protein misfolding inside cells: The case of huntingtin and Huntington's diseaseSemantic proximity Read ↗

Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.